Core Insights - Tevogen Bio has developed a significant asset portfolio since its founding in 2020 while maintaining expenditures under $40 million, which is a fraction of the industry norm [1][3] - The company focuses on building a disciplined and sustainable business model in the biotech sector, particularly in immunotherapy for infectious diseases and cancers [2][4] - Tevogen's leadership emphasizes the importance of preserving shareholder value and being cautious about equity dilution when considering financing options [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf, genetically unmodified T cell therapies targeting infectious diseases, cancers, and neurological disorders [4][5] - The company has reported positive safety data from its proof-of-concept clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents [4] - Tevogen's leadership believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating innovative business models to sustain medical innovation [5]

WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen. In tandem with this announcement, Tevogen Bio reaffirms ...

Core Viewpoint - Tevogen Bio has appointed Anthony Tarantino as its new Patient Advocate, leveraging his extensive experience in firefighter safety and community advocacy to enhance patient-centered healthcare initiatives, particularly for immunocompromised cancer patients and those suffering from Long COVID [1][3][4]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified T cell therapeutics for treating infectious diseases, cancers, and neurological disorders [5][6]. - The company aims to address significant unmet needs in large patient populations and believes that sustainability and commercial success depend on ensuring patient accessibility through advanced science and innovative business models [5]. Leadership and Advocacy - Anthony Tarantino previously served as President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters Association of New Jersey, where he advanced policies for firefighter health and safety, including legislation for regular cancer screenings [2][3]. - His advocacy work is rooted in public health principles, focusing on access to life-saving resources and legislative engagement, which aligns with Tevogen's mission [3][4]. Current Initiatives - Tarantino's appointment is timely as Tevogen advances its investigational therapy, TVGN 489, aimed at treating SARS-CoV-2 in cancer patients and those with Long COVID [4]. - The company has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned, including three granted patents and several pending patents [5].

PRINCETON JUNCTION, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Alpha Capital Corp ("Alpha"), a global merchant bank, is pleased to announce that it has been retained as the exclusive financial advisor to CD8 Technology Services, LLC ("CD8 Technology") in connection with financing a real estate facility whose primary focus is developing and manufacturing biologic products for cell therapy. By eliminating barriers to entry, in terms of capital and time to build GMP capabilities at scale, this venture will expedi ...

CD8 Technology Services, LLC ("CD8 Technology") to provide turn-key facility for Tevogen Bio Reinforces Tevogen Bio's commitment to preserving shareholder value Expected to further enhance Tevogen Bio's ambitious growth agenda WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, took si ...

WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company's proprietary ExacTcell™ technology, TVGN 489, designed to treat SARSCoV-2 infections in immunocompromised oncology patients, and a subgroup of patients w ...

WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to provide further updates on the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas by the end of this week. The revenue forecast for the two therapeutic areas is approximate ...

WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomenberg sold shares. Tevogen's Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations relating to the ...

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell™ technology, designed to create accessible and disease ...

Total eligible patients in the US exceed 2 million. Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment. Reflects business philosophy of commercial success through patient accessibility. WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, t ...